Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study follows Patients' pain and odor relief from skin condition treatment

NCT ID NCT06444087

Ongoing Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how patients with hidradenitis suppurativa (HS) experience their symptoms after starting a medication called secukinumab. Researchers will follow 192 adults in France for up to two years, asking them to report on pain, oozing, and odor. The goal is to see how these symptoms and quality of life change in a real-world treatment setting.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Nice, France, 06000, France

  • Novartis Investigative Site

    Antony, 92160, France

  • Novartis Investigative Site

    Bordeaux, 33075, France

  • Novartis Investigative Site

    Brest, 29609, France

  • Novartis Investigative Site

    Calais, 62100, France

  • Novartis Investigative Site

    Dijon, 21000, France

  • Novartis Investigative Site

    La Rochelle, 17019, France

  • Novartis Investigative Site

    Le Mans, 72000, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Lorient, 56322, France

  • Novartis Investigative Site

    Lyon, 69003, France

  • Novartis Investigative Site

    Marseille, 13008, France

  • Novartis Investigative Site

    Martigues, 13500, France

  • Novartis Investigative Site

    Montpellier, 34090, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Paris, 75014, France

  • Novartis Investigative Site

    Rodez, 12000, France

  • Novartis Investigative Site

    Rouen, 76031, France

  • Novartis Investigative Site

    Saint-Mandé, 94160, France

  • Novartis Investigative Site

    Saint-Pierre, 97410, France

  • Novartis Investigative Site

    Toulouse, 31400, France

  • Novartis Investigative Site

    Vannes, 56000, France

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA